Stansberry Venture Technology, Dave Lashmet’s $1 trillion renaissanceYesterday’s Stansberry Digest carried the above teaser. It’s a small US-based chip company. Crucially, it actually makes its own chips within the US (rather than contracting out the production). Anyone any ideas? After years of membership, my first time posting, so forgive me if I’ve overstepped some protocols. I did have a look through the […]
Articles
Yesterday we got a ton of questions about another full-throated pitch for a high-end Stansberry newsletter, this time Dave Lashmet’s Stansberry Venture Technology, which they say has a list price of $5,500 and is typically offered in promotions, as is the case today, for $2,500/yr, no refunds (as with most publishers, Stansberry offers a brief […]
This is the pitch that sent a bucketful of questions heading our way yesterday: “Last Week’s Major FDA Announcement Officially Kick-started a Massive Opportunity “A disease that 42% of Americans suffer from can now be cured. Our analyst tracked this story from the beginning, and he’s finally breaking his silence to reveal the name of […]
President Trump’s “germophobia” and longstanding reluctance to shake hands or hug people hasn’t saved him from exposure to the coronavirus, we learn this morning — both the President and First Lady have tested positive, following the announcement yesterday that Hope Hicks was going into quarantine after a positive test — but perhaps it will help […]
This article was originally posted on August 27, when we first saw these ads circulating… apparently lots of folks missed it, and the ads are running hot and heavy again, so we’re re-posting it here to help answer a flood of new reader questions. The stock teased has popped 40-50% or so on the Stansberry […]
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
Dave Lashmet has been a biotech/medical analyst and sometimes a newsletter editor at Stansberry for a long time, and the latest iteration of his high-end newsletter is now called Stansberry Venture Technology (currently “on sale” for $2,500, no refunds)… and it’s now being promoted with a “cure for cancer” spiel, so we obviously all want […]
The ads that get the most attention tend to be either those that are most dramatically distributed, with seemingly every single email address getting multiple copies… or those that come with a big promise and a very high price. Today’s topic of interest is the latter, since we’re told that Stansberry Venture Value’s Dave Lashmet […]
Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]
Alzheimer’s Disease always gets a lot of attention from newsletter publishers, readers and investors — not only because we all know someone who suffers from this terrible malady, but because we know that the current treatments are ineffective and the market is huge… which means that any real solutions or more effective treatments could create […]
Dave Lashmet is sending around an ad for his Stansberry Venture service that he says highlights an investment that is “Three Times Better Than Any Opportunity I’ve Ever Found.” So that sounds pretty good, right? One nice thing about being an investment chatterer is that you can have a short memory — each idea that […]
Dave Lashmet has teased a handful of biotech stocks since starting the Stansberry Venture service a couple years ago, and they usually get a lot of attention from our readers — so the new ad from Lashmet today has been forwarded to me dozens of times already. And while I’m not sure we’ll be able […]
Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]
That’s a mysterious headline, right? The pitch we’re looking at today is from Dave Lashmet at Stansberry, who’s selling his Stansberry Venture newsletter for $5,000 — and the carrot he’s dangling to get you to subscribe is this “most disruptive biotech discovery” … which, it turns out, is a form of radiation therapy that, in […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I am listening to this too. It's a pink sheet company with 350K shares traded daily. It does have to do with semiconduct...
Just being a Stansberry Alliance Member does not allow you access to Stansberry Venture Tech subscription of Dave La...
Thanks to Author/Editor: Dave Lashmet for reading and going through this long and tedious Stansberry stock tip/newslette...
Travis, could you please investigate the obesity drug company that Dave Lashmet is hinting about for Stansbury Research?...
Earlier this year (or maybe it was late last year), I listened to a Stansberry infomercial where Steve Sjuggerud gave hi...
I think you're right, we covered that one here: https://www.stockgumshoe.com/reviews/stansberry-venture/stansberry-ventu...
It's always interesting watching how the various parts of the Agora "empire" deal with the same stock. Here Stansberry'...
Cancer briefing nov 15 stansberry Dave lashmet and doc eifrig claims new cancer breakthrough with 500 percent gains this...
I like the stuff that I've read from Dave Lashmet. I think that he's a straight shooter. If he says buy INO, then I'...
This all seemed familiar to me and so I looked up some old data dated February 2006 and Dave Lashmet was teasing about t...
Re: biotech mergers and acquisitions Although the surge in M&A activity has some observors warning of a "bubble" in ...